Wednesday, January 18, 2023, San Francisco, California, 7:15 PM – 9:15 PM Pacific Time (10:15 PM – 12:15 AM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer

Part 1 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine
and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Chair, ACCRU Research Consortium
Phoenix, Arizona

Scott Kopetz, MD, PhD
Professor and Deputy Chair
Department of Gastrointestinal Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas


John Strickler, MD
Associate Professor
Duke University
Durham, North Carolina

Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Moderator
Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee


This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc.
Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 9:15 PM — Educational Dinner Meeting

MODULE 1: Current and Future Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC)

  • Frequency of BRAF mutations and HER2 overexpression in patients with mCRC; indications, timing and optimal approaches for testing
  • Updated data from the Phase II DESTINY-CRC01 study of trastuzumab deruxtecan (T-DXd) for patients with HER2-expressing mCRC
  • Spectrum, incidence and severity of toxicities, including interstitial lung disease, with T-DXd
  • Ongoing evaluation of T-DXd (eg, DESTINY-CRC02 trial) and potential role in nonresearch management of mCRC
  • Design, eligibility criteria and recently reported findings from the pivotal Phase II MOUNTAINEER trial evaluating tucatinib/trastuzumab for previously treated HER2-positive mCRC
  • Spectrum and frequency of toxicities observed with tucatinib/trastuzumab in patients with mCRC
  • Published research findings with various HER2-directed strategies (eg, trastuzumab/pertuzumab, lapatinib/trastuzumab) for mCRC
  • Early findings (eg, from the ANCHOR CRC trial) with and ongoing evaluations (eg, the BREAKWATER trial ) of first-line BRAF-targeted therapy
  • FDA approval of encorafenib/cetuximab and appropriate integration into clinical practice for patients with BRAF V600E-mutant mCRC

MODULE 2: Integrating and Optimizing Immune Checkpoint Inhibitors in Therapy for mCRC

  • Long-term efficacy and safety results, including final overall survival findings, from the Phase III KEYNOTE-177 study evaluating front-line pembrolizumab versus chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) mCRC
  • FDA approval of pembrolizumab as first-line therapy and implications for clinical practice
  • Available findings with nivolumab/ipilimumab for previously untreated MSI-H/dMMR mCRC; current role, if any, of dual immune checkpoint inhibition for newly diagnosed disease
  • Rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab into therapy for progressive MSI-H/dMMR mCRC
  • Early results with and ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for MSI-H/dMMR advanced CRC
  • Biologic rationale for, available data with and ongoing investigation of immune checkpoint inhibition for microsatellite-stable (MSS) mCRC
  • Published clinical trial findings from the Phase II LEAP-05 trial documenting the efficacy and safety of lenvatinib/pembrolizumab for patients with previously treated MSS CRC
  • Design, eligibility criteria and key endpoints of the Phase III LEAP-017 trial comparing lenvatinib/pembrolizumab to standard therapy for previously treated MSS mCRC
  • Clinical activity and safety observed with cabozantinib in combination with anti-PD-1/PD-L1 antibodies in patients with MSS mCRC in early-phase trials (eg, COSMIC-021 cohort 16, CAMILLA cohort 2)
  • Pharmacologic and pharmacodynamic similarities and differences between cabozantinib and XL092
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III STELLAR-303 trial comparing XL092 in combination with atezolizumab to regorafenib for relapsed/refractory (R/R) MSS mCRC
  • Available data with and ongoing investigation of other immune checkpoint inhibitor-based strategies for patients with MSS mCRC

MODULE 3: Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC

  • Correlation between the right- or left-side location of the primary tumor and outcomes with EGFR antibody-based regimens among patients with mCRC
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III PARADIGM trial evaluating modified FOLFOX6 with either panitumumab or bevacizumab as first-line therapy for RAS wild-type mCRC; implications for treatment decision-making
  • Long-term efficacy and safety findings from pivotal Phase III trials assessing regorafenib and TAS-102 for patients with multiregimen-relapsed CRC
  • Available data with and potential role of TAS-102 in combination with bevacizumab or other systemic agents for mCRC and/or in earlier disease stages
  • Factors in the selection and sequencing of regorafenib, TAS-102 and anti-EGFR antibody therapy for progressive mCRC; utility of rechallenge with EGFR antibodies after disease progression

MODULE 4: Promising Agents and Strategies for Patients with mCRC

  • Incidence of KRAS G12C mutations in mCRC; mechanism of action of sotorasib and adagrasib
  • Early results with and ongoing evaluation of KRAS G12C inhibitors for KRAS p.G12C-mutant mCRC
  • Rationale for and early data with KRAS-targeted agents in combination with anti-EGFR therapy for mCRC
  • Similarities and differences in the design and eligibility criteria of the Phase III CodeBreak 300 and KRYSTAL-10 trials evaluating sotorasib and adagrasib, respectively, in combination with an anti-EGFR antibody for advanced mCRC
  • Mechanism of action of and available clinical research data with fruquintinib for R/R mCRC
  • Design, eligibility criteria and emerging efficacy and safety findings with fruquintinib for patients with mCRC who have experienced disease progression on or are intolerant to standard therapies
  • Biologic rationale for the investigation of agents targeting alternative immune checkpoints in CRC
  • Design, eligibility criteria and key efficacy and safety endpoints of the Phase III RELATIVITY-123 study assessing nivolumab/relatlimab versus regorafenib or
  • Frequency of HER3 overexpression in patients with mCRC and biologic rationale for the investigation of patritumab deruxtecan for R/R mCRC
  • Other promising agents and strategies under investigation for mCRC

MODULE 5: The Changing Management Paradigm for Localized CRC

  • Benefits and limitations of current approaches for surveillance and treatment decision-making for patients with localized CRC who have undergone curative-intent therapy
  • Mechanistic rationale for the use of ctDNA/minimal residual disease (MRD) monitoring for localized CRC; available data (eg, from the CIRCULATE-Japan trial)
  • Active studies (eg, CIRCULATE-US, BESPOKE CRC) examining the clinical utility of ctDNA/MRD testing in guiding treatment decision-making and monitoring for recurrence; potential clinical impact
  • Biologic rationale for and published research findings with the use of immune checkpoint inhibitors in patients with localized CRC
  • Available and emerging findings from the Phase II NICHE and NICHE-2 trials investigating the efficacy and safety of nivolumab/ipilimumab as neoadjuvant therapy for patients with nonmetastatic CRC with and without high MSI
  • Ongoing Phase III trials evaluating the role of immune checkpoint inhibitors in therapy for nonmetastatic CRC

Target Audience
This activity is intended for medical and radiation oncologists, nurses, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Optimize the use of adjuvant chemotherapy for localized colorectal cancer (CRC), considering the influence of various clinical and biologic factors (patient age, performance status, disease stage, et cetera).
  • Develop a long-term plan to guide the selection and sequencing of therapies for metastatic CRC (mCRC), considering the patient’s biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
  • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into disease management.
  • Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future roles of various investigational approaches.
  • Evaluate available data with and FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient mCRC, and optimally select patients for this type of treatment.
  • Apply available and emerging research in selecting and sequencing later-line therapeutic options for patients with multiregimen-relapsed mCRC.
  • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to refer appropriate patients for study participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical and radiation oncologists, nurses, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of gastrointestinal cancers.

There is no fee to participate in this hybrid event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.